



# NANOPILOT

*A Pilot Plant for the Production of Nanopharmaceuticals in Compliance with GMP*

## DELIVERABLE 3.9

***Deliverable title:*** Third Workshop in translational nanomedicine (III)

***Responsible:*** CIDETEC

***Due Date (in months):*** 42



DELIVERABLE DATA	
Number	3.9
Title	Third Workshop in translational nanomedicine (III)
Type (R, DEM, DEC, OTHER) <sup>1</sup>	OTHER
Dissemination Level (PU, CO, CI) <sup>2</sup>	PU
Submission Date	04/04/2018
Institution Responsible	CIDETEC
Editor Name	Ana Benito, Iraida Loinaz and Luisa Ruiz

**ABSTRACT:**

This deliverable is the summary of the breakout session organized by NanoPilot project in Farmaforum (Madrid, Spain) as the third workshop on translational nanomedicine.

**KEY WORDS:**

Workshop, dissemination, breakout session, Farmaforum, translational nanomedicine

---

<sup>1</sup> **R:** Document, Report; **DEM:** Demonstrator, Pilot, Prototype; **DEC:** Websites, patent fillings, videos, etc.

<sup>2</sup> **PU:** Public; **CO:** Confidential. Only for members of the Consortium (including the Commission Services); **CI:** Classified, as referred to in Commission decision 2001/884/EC

## TABLE OF CONTENT

<b>1</b>	<b>INTRODUCTION .....</b>	<b>1</b>
<b>2</b>	<b>SUMMARY OF THE SESSION IN FARMAFORUM.....</b>	<b>1</b>
2.1.1	First speaker: Maria Jose Alonso (USC) .....	2
2.1.2	Second speaker: Iraida Loinaz (CIDETEC Institute for Nanomedicine) .....	2
2.1.3	Third speaker: Africa Barrientos (Midatech Pharma España SLU) .....	2
2.1.4	Fourth speaker: Salvador Borrós (Sagetis Biotech).....	3
<b>3</b>	<b>SOME PHOTOS DURING THE SESSION.....</b>	<b>3</b>

## 1 INTRODUCTION

The third workshop in translational nanomedicine was organized in Farmaforum (Madrid, March 2018). (<http://farmaforum.es/>)

Farmaforum consists of an exhibition area and a program of conferences and workshops. It is one of the most important event of the Pharmaceutical Industry in Spain, extending its subject and sharing synergies with the biotechnology industry and the cosmetics industry through special areas Biotechforum and Cosméticaforum.

The third Workshop on Translational Nanomedicine took place on the 7<sup>th</sup> of March from 15.30h to 17.30h. Luisa Ruiz, QA/QP at CIDETEC Institute for Nanomedicine and part of the NanoPilot project, was the chairwoman of this workshop, where the following speakers took part:

- Iraida Loinaz –Director of the CIDETEC Institute for Nanomedicine and NanoPilot project coordinator.
- M<sup>a</sup> José Alonso – Professor of Pharmacy and Pharmaceutical Technology and Full Professor at the University of Santiago de Compostela (USC) and Principal Researcher at CIMUS Research Institute. Partner in NanoPilot project.
- África Barrientos (in place of Justin Barry)– Head of Nanoparticle development at Midatech Pharma España SLU. Midatech is coordinating NanoFacturing H2020 project.
- Salvador Borrós – Scientific leader, co-founder and member of the Board at Sagetis Biotech. Full Professor at Institut Químic de Sarrià (IQS), Ramon Llull University.

## 2 SUMMARY OF THE SESSION IN FARMAFORUM

Four speakers were invited to talk about the real advantages and benefits of nanomedicine. During the event several questions were addressed, such as:

- Are there areas of research in which nanomedicine could have a greater impact or applicability (oncology, immunology, to name a few) than in others?
- What would be the main barriers to the technology transfer of these new developments in Nanomedicine?
- Is there a lack of multidisciplinary teams to support and guide these developments? (Clinical researchers; regulatory consultants; ...)
- What is the position of large pharmaceutical companies with regard to nanomedicine?

- Best ways to address regulatory guidelines and GMP manufacturing.
- Financing model: from basic research to venture capital funds.
- How to work on translational nanomedicine at R&D level to go further and faster with new nano developments?
- What is the future of the Nanomedicine?

Each speaker gave a speech (10-12 minutes approximately) followed by some questions.

### **2.1.1 First speaker: Maria Jose Alonso (USC)**

M<sup>a</sup> José Alonso is a researcher of great international prestige, pioneer in numerous discoveries in the area of pharmaceutical technology and Nanomedicine. She is the author of more than 240 scientific articles and the inventor of more than 20 patent families.

She currently holds important positions in several scientific associations (for example, she was appointed president of the Controlled Release in late 2017) and has received numerous awards throughout her career for the quality of her work.

Under the title "*Nanotechnology: improving the safety and efficacy of medicines*", he shared with the public the point of view of his, internationally renowned, research group. She showed some examples in which nanotechnology has shown an improvement in the efficacy and safety of several drugs.

### **2.1.2 Second speaker: Iraida Loinaz (CIDETEC Institute for Nanomedicine)**

Iraida Loinaz has an extensive experience in the development of innovative materials in the field of Biomedicine and their transfer to industry.

Among the strategic collaborations of CIDETEC Institute for Nanomedicine, it is worth mentioning the coordination of three Horizon 2020 projects, among which is the Nanopilot project, consisting of the construction of a pilot plant for the production of nano-pharmaceuticals under GMP.

She showed the point of view of a technology center in the transfer of technology from the laboratory scale to its GMP manufacturing, also exposing the knowledge generated in the NanoPilot project.

### **2.1.3 Third speaker: Africa Barrientos (Midatech Pharma España SLU)**

África Barrientos has over 15 years' experience in the preparation and production of gold glyconanoparticles, especially for applications in the pharmaceutical industry.

She is currently the Head of the Technology Transfer Laboratory at Midatech Pharma, a company dedicated to the design, development, synthesis and production of nanomedicine based on biocompatible nanoparticles, with activity mainly focused on metabolic diseases and oncology. In addition, Midatech is coordinating NanoFacturing H2020 project.

She moved to a more advanced stage of the nano-drugs development, the clinical development of nano-drugs, and showed Midatech's experience based on the barriers they have encountered in developing their products. He spoke about the design of clinical trials and whether they have needed adaptations in methodology to obtain evidence of the efficacy and/or safety of the drug.

#### **2.1.4 Fourth speaker: Salvador Borrós (Sagetis Biotech)**

Salvador Borrós is co-founder and member of the Board at Sagetis Biotech. Sagetis is a spin-off of the materials research group of the Institut Quimic de Sarrià (IQS), dedicated to the development of controlled drug release technologies to solve medical needs not covered yet. As an example, the polymeric coating of oncolytic viruses to protect them from neutralizers, thus increasing their permanence in the blood for use in the treatment of cancer.


He spoke of Sagetis' experience in the development of nano-drugs from both a scientific and a clinical trial point of view. He gave his vision on how to obtain financing that increases the value of a project and also explained the weight that nanotechnology has (or can have) in Sagetis' product portfolio.

### **3 SOME PHOTOS DURING THE SESSION**

In the following pages there are some photos of the event.



**Photo 1:** Luisa Ruiz presenting Maria Jose Alonso to the audience



**Photo 2:** Maria José Alonso during her presentation





**Photo 3:** Questions time



**Photo 4:** Iraida Loinaz during her presentation





**Photo 5:** Africa Barrientos during her presentation



**Photo 6:** Salvador Borrós during her presentation